Sep 2026· European Journal of Pharmacology· pp.
179344
· 0 citations· 46 references
Medicine
TL;DR
Mogrol mitigates warm HIRI, at least in part, by activating the PI3K/AKT/GSK3β signaling pathway, thus highlighting its potential as a naturally derived candidate for liver protection.
Abstract
Background
Warm hepatic ischemia-reperfusion injury (HIRI) is a common complication of liver surgery that significantly impairs clinical outcomes, and effective therapeutic strategies remain limited. Mogrol is a bioactive component derived from Siraitia grosvenorii that exhibits potent anti-inflammatory and antioxidant properties; however, its role in warm HIRI and the underlying mechanisms remain largely unexplored.
Methods
The effects of Mogrol were investigated using an in vivo warm hepatic I/R model with mice and an in vitro hypoxia/reoxygenation model with AML12 cells. Mogrol was administered with or without the PI3K inhibitor LY294002. Liver function, histopathology, oxidative stress, inflammatory responses, and mitochondrial function were assessed using biochemical assays, fluorescence staining, transmission electron microscopy (TEM), and adenosine triphosphate (ATP) measurements. Transcriptomic analysis, molecular docking, cellular thermal shift assay (CETSA), and western blotting were performed to explore the underlying mechanisms.
Results
Mogrol pretreatment significantly reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, alleviated hepatic necrosis, suppressed oxidative stress and inflammatory responses, restored mitochondrial ultrastructure, stabilized mitochondrial membrane potential (MMP), inhibited mitochondrial permeability transition pore (mPTP) opening, enhanced ATP production, and attenuated mitochondria-mediated apoptosis in both in vivo and in vitro models. These protective effects were partially reversed by LY294002.
Conclusion
Mogrol mitigates warm HIRI, at least in part, by activating the PI3K/AKT/GSK3β signaling pathway, thus highlighting its potential as a naturally derived candidate for liver protection.
ILL attenuates HIRI by simultaneously elevating SIRT1 expression and activating its deacetylase function, thereby restraining IRE1α-dependent ERS and subsequent hepatic injury, highlighting ILL as a promising therapeutic candidate for the management of perioperative HIRI.
Hao Li, Zhen-Yu Guan, Wendong Li et al.· International Immunopharmaco...· 0 citations
Hepatic ischemia-reperfusion injury (HIRI) remains a critical complication in liver surgery with limited pharmacological options, and while Farrerol (FA), a natural dihydroflavone, has shown protective effects in other organ IR models, its role in HIRI has never been explored. In this study, we established a murine mod...
Hong-Liang Liang, Jian-Sen Lu, Hao Pan et al.· International Immunopharmaco...· 0 citations
Hepatic ischemia-reperfusion injury (HIRI) is a major challenge in liver surgery, and effective pharmacological interventions are lacking. Salvianolic acid C (SaC) has shown protective effects in various pathologies, but its role in HIRI remains unclear. This study investigated whether SaC protects against HIRI and elu...
Pingping Qiao, A. Tulahong, Xin-Lu Xu et al.· Phytotherapy Research· 0 citations
Tar improved CIRI induced inflammation and ferroptosis through regulating the AKT/NF‐κB pathway and reversed the protective effects of Tar in OGD/R‐induced PC12 cells.
Zhengfei Yang, Zhen-Wu Zhao· The FASEB Journal· 0 citations
BACKGROUND
Ischemic stroke remains associated with substantial neurological disability, and effective strategies for cerebral ischemia-reperfusion injury (CIRI) are limited. Dihydromyricetin (DHM) has shown neuroprotective properties in experimental neurological disorders, but its effects and associated molecular mecha...
Ying-Ying Tang, Xiao-Dan Wang, Jia-Yu Ye et al.· Phytomedicine· 0 citations
Findings indicate that TZ may protect against CIRI by suppressing apoptosis and neuroinflammation through activation of the PI3K/AKT/mTOR signaling pathway, thereby providing preclinical evidence for its potential repurposing as a treatment for ischemic stroke.
Lin-Lin Xie, Yu-Kun Ping, Jie Zhao et al.· Current Neuropharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.